title: Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
abstract: A multicenter analysis was conducted to evaluate the main prognostic factors driving survival after radioembolization using yttrium-90-labeled resin microspheres in patients with hepatocellular carcinoma at eight European centers. In total, 325 patients received a median activity of 1.6 GBq between September 2003 and December 2009, predominantly as whole-liver (45.2%) or right-lobe (38.5%) infusions. Typically, patients were Child-Pugh class A (82.5%), had underlying cirrhosis (78.5%), and had good Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 0-1; 87.7%), but many had multinodular disease (75.9%) invading both lobes (53.1%) and/or portal vein occlusion (13.5% branch; 9.8% main). Over half had advanced Barcelona Clinic Liver Cancer (BCLC) staging (BCLC C, 56.3%) and one-quarter had intermediate staging (BCLC B, 26.8%). The median overall survival was 12.8 months (95% confidence interval, 10.9-15.7), which varied significantly by disease stage (BCLC A, 24.4 months [95% CI, 18.6-38.1 months]; BCLC B, 16.9 months [95% CI, 12.8-22.8 months]; BCLC C, 10.0 months [95% CI, 7.7-10.9 months]). Consistent with this finding , survival varied significantly by ECOG status, hepatic function (Child-Pugh class, ascites, and baseline total bilirubin), tumor burden (number of nodules, alpha-fetoprotein), and presence of extrahepatic disease. When considered within the framework of BCLC staging, variables reflecting tumor burden and liver function provided additional prognostic information. The most significant independent prognostic factors for survival upon multivariate analysis were ECOG status, tumor burden (nodules >5), international normalized ratio >1.2, and extrahepatic disease. Common adverse events were: fatigue, nausea/vomiting, and abdominal pain. Grade 3 or higher increases in bilirubin were reported in 5.8% of patients. All-cause mortality was 0.6% and 6.8% at 30 and 90 days, respectively.
  
  
  CONCLUSIONS
  This analysis provides robust evidence of the survival achieved with radioembolization, including those with advanced disease and few treatment options.
authors: Liver Unit, Clinica Universidad de Navarra and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), Pamplona, Spain. bsangro@unav.es
authors: Bruno
authors: B
authors: Sangro
authors: Livio
authors: L
authors: Carpanese
authors: Roberto
authors: R
authors: Cianni
authors: Rita
authors: R
authors: Golfieri
authors: Daniele
authors: D
authors: Gasparini
authors: Samer
authors: S
authors: Ezziddin
authors: Philipp M
authors: PM
authors: Paprottka
authors: Francesco
authors: F
authors: Fiore
authors: Mark
authors: M
authors: Van Buskirk
authors: Jose Ignacio
authors: JI
authors: Bilbao
authors: Giuseppe Maria
authors: GM
authors: Ettorre
authors: Rita
authors: R
authors: Salvatori
authors: Emanuela
authors: E
authors: Giampalma
authors: Onelio
authors: O
authors: Geatti
authors: Kai
authors: K
authors: Wilhelm
authors: Ralf Thorsten
authors: RT
authors: Hoffmann
authors: Francesco
authors: F
authors: Izzo
authors: Mercedes
authors: M
authors: Iñarrairaegui
authors: Carlo Ludovico
authors: CL
authors: Maini
authors: Carlo
authors: C
authors: Urigo
authors: Alberta
authors: A
authors: Cappelli
authors: Alessandro
authors: A
authors: Vit
authors: Hojjat
authors: H
authors: Ahmadzadehfar
authors: Tobias Franz
authors: TF
authors: Jakobs
authors: Secondo
authors: S
authors: Lastoria